In addition to coronary artery disease, drug-eluting balloons have expanded their applications to peripheral arterial disease (PAD). PAD, caused by the narrowing of peripheral arteries, can lead to severe limb ischemia and compromise patients' quality of life. Drug Eluting Balloon have shown promise in improving outcomes for patients with femoropopliteal lesions, a common manifestation of PAD. By delivering antiproliferative drugs directly to the diseased vessel, DEBs help to inhibit neointimal hyperplasia and improve vessel patency.
Drug Eluting Balloonare angioplasty balloons that are semi-compliant and covered with anti-proliferative medications that are released into the blood artery walls during balloon inflation, typically at nominal pressures. These balloons dramatically reduce cellularity and do away with the necessity for repeated vascularization.The vessel wall processes the efficient homogeneous administration of anti-proliferative medications through an inflated balloon in the drug-eluting balloon, a non-stent technology. The balloon technology is based on the idea of targeted medication delivery, which promotes quick artery wall repair and inhibits the growth of smooth muscle cells. In preclinical and randomised clinical trials, DEB technology proved secure and effective for patients with in-stent restenosis.
Read More @ https://cmibloginsight.blogspot.com/2023/06/drug-eluting-balloon-advancing.html
Comments
0 comment